Loading...
Loading...
Merck
MRK
today announced the initiation of a clinical trial to evaluate the
combination of the company's investigational anti-PD-1 immunotherapy,
MK-3475, and GlaxoSmithKline's
GSK orally administered kinase inhibitor,
pazopanib, in advanced renal cell carcinoma.
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
